Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$7.41
$0.62(8.37%)
At close: 4:00 PM EDT
$7.41
$0.62(8.37%)
Day’s Range― - ―
52-Week Range$3.27 - $13.67
Previous CloseN/A
Volume420.10K
Average Volume (3M)1.25M
Market Cap
$505.26M
Enterprise Value$376.16
Total Cash (Recent Filing)$199.43M
Total Debt (Recent Filing)$33.00M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 18, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding61,843,445
10 Day Avg. Volume1,152,977
30 Day Avg. Volume1,250,395
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.33Price Target Upside309.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing CapacityA five-year manufacturing and testing agreement with a CDMO creates durable commercial readiness by securing scalable supply for miv-cel. This reduces execution risk around product launch, supports BLA submission workstreams, and lowers operational bottleneck risk during commercialization.
Low Financial LeverageVery low leverage and meaningful equity provide structural runway for development spending and lower insolvency risk versus highly levered peers. This financial flexibility supports funding clinical programs or negotiating non-dilutive partnerships while outcomes remain binary.
Experienced Commercial & Finance HiresBringing a seasoned Chief Commercial Officer with rare-disease launch experience and an industry CFO strengthens long-term commercialization planning, pricing/market access strategy, and capital allocation—critical capabilities as the company shifts toward potential product launches.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow materially shortens runway absent new funding or revenue. Persistent burn forces recurring financing choices, risks dilution or restrictive debt, and constrains multi-program investment even if lead assets progress favorably.
No Revenue BaseZero revenues make the business outcome-dependent on clinical success and regulatory approval. Without diversified or recurring revenue, the company faces high binary commercial risk and limited internal cash generation to fund launches or meet covenant targets.
Restrictive Financing TermsAmended term loan extends access to capital but links future tranches to revenue/clinical milestones and introduces covenants. These structural constraints can limit strategic flexibility, pressure near-term decisions, and raise the risk of covenant-triggered restrictions if milestones slip.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $3.27 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $505.26M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 93 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.678 by $0.048.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.69.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 61,843,445 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.678. Following the earnings report the stock price went up 0.374%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.33 (309.36% Upside)
$30.33 (309.36% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$30.33
▲(309.36% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
22.84% Insiders
5.77% Mutual Funds
34.15% Other Institutional Investors
28.06% Public Companies and
Individual Investors